Disclosures under Regulation 30 of Listing Regulations - Sparc Life

2024 - 25

Intimation under regulation 30 of LODR

View More

Intimation regarding SMT

View More

Intimation of Senior Management Team

View More

Resignation of CFO_Disclosure under regulation 30 of SEBI LODR

View More

Results from the Planned Interim Analysis 10-04-2024

View More

Disclosure under Regulation 30(5) of SEBI LODR

View More
2023 - 24

Investor Meet 14-02-2024

View More

Intimation of Revamping the Website of the Company

View More

Investor presentation 07-01-2024

View More

Investor Presentation 06-01-2024

View More

Press Release Sparc to Present at the 42nd Annual J.P Morgan Healthcare Conference

View More

Intimation of Schedule of Analyst Institutional Investor Meeting

View More

Sparc to Provide Update on Vodobatinib Parkinson's Disease program

View More

Sparc Enters into an Exclusive Worldwide License Agreement for SCD-153 with JHU and IOCB

View More

Intimation of incorporation of a Wholly Owned Subsidiary

View More

Change in Senior Management Dr Chitturi Trinadha Rao

View More

Intimation for an appointment of Company Secretary & Compliance Officer and Key Managerial Personnel

View More

Change in Key Managerial Personnel

View More

Intimation for ongoing litigations

View More
2022 - 23

Intimation on IT Security Incident

View More
2021 - 22

Announcement under Reg 30

View More

Phase 3 Clinical Trial of PDP-716

View More
2019 - 20

Investor presentation on updates on R&D Pipeline

View More

Press Release Audio Playback for Update on R&D Pipeline

View More

Resignation by Mr. Mark Simon as Independent Director of the Company

View More

SPARC Receives Orphan Drug Designation from the USFDA for Phenobarbital for the Treatment of Patients with Neonatal Seizures

View More

Update on Taclantis

View More

Update on TACLANTIS™ (Paclitaxel Injection Concentrate for Suspension) NDA

View More
2018 - 19

Intimation for inter-se change in the shareholding of certain promoter group entities on account of scheme of amalgamation

View More
2017 - 18

Elepsia-UpdateUpdate on Elepsia XRTM (Levetiracetam extended-release tablets 1000 mg and 1500 mg) NDA

View More
2016 - 17

Indirect acquisition of controlling stake in the Company by Shanghvi Finance Pvt. Ltd. ('SFPL') making SFPL the Holding Company of SPARC

View More

Receipt of demand notice under section 156 of the Income Tax Act, 1961

View More

Update on Xelpros

View More
2015 - 16

Authorized Key Managerial Personnez to determine materiality of an event or information

View More

Copyright @ 2024. All Rights Reserved.

Follow Us :